Haemonetics (NYSE:HAE) Issues FY25 Earnings Guidance

Haemonetics (NYSE:HAE - Get Free Report) updated its FY25 earnings guidance on Thursday. The company provided earnings per share guidance of $4.45-4.75 for the period, compared to the consensus earnings per share estimate of $4.59. The company issued revenue guidance of ~$1.37-1.41 billion, compared to the consensus revenue estimate of $1.40 billion. Haemonetics also updated its FY 2025 guidance to 4.450-4.750 EPS.

Haemonetics Price Performance

NYSE HAE traded up $8.37 during trading on Thursday, reaching $86.53. The company's stock had a trading volume of 1,551,654 shares, compared to its average volume of 546,099. The stock has a market capitalization of $4.43 billion, a PE ratio of 38.79, a P/E/G ratio of 1.15 and a beta of 0.32. The company has a debt-to-equity ratio of 1.35, a current ratio of 3.76 and a quick ratio of 2.33. The firm has a fifty day moving average of $75.42 and a 200 day moving average of $82.60. Haemonetics has a one year low of $70.25 and a one year high of $97.97.

Haemonetics (NYSE:HAE - Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The medical instruments supplier reported $1.02 earnings per share for the quarter, missing the consensus estimate of $1.03 by ($0.01). Haemonetics had a return on equity of 21.86% and a net margin of 8.61%. The company had revenue of $336.17 million during the quarter, compared to the consensus estimate of $335.08 million. During the same quarter last year, the company posted $1.05 earnings per share. The firm's revenue for the quarter was up 8.0% on a year-over-year basis. Analysts expect that Haemonetics will post 4.57 EPS for the current fiscal year.

Analysts Set New Price Targets

HAE has been the topic of a number of research analyst reports. CL King began coverage on Haemonetics in a research note on Friday, September 13th. They issued a "buy" rating and a $116.00 target price on the stock. Barrington Research reiterated an "outperform" rating and set a $108.00 price objective on shares of Haemonetics in a research report on Monday, September 23rd. BTIG Research initiated coverage on Haemonetics in a research report on Tuesday, September 10th. They issued a "buy" rating and a $112.00 target price for the company. Bank of America began coverage on shares of Haemonetics in a research report on Wednesday, September 11th. They set a "neutral" rating and a $85.00 price target on the stock. Finally, Citigroup lowered their price objective on shares of Haemonetics from $94.00 to $85.00 and set a "neutral" rating for the company in a report on Thursday, August 22nd. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $106.14.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.